Storm Therapeutics closed a $56 million Series C to advance STC-15, its METTL3-targeting RNA enzyme inhibitor, through Phase 2 development in sarcoma. The company said the financing will support continued Phase 2 execution across selected myo- and liposarcomas, following earlier Phase 1 observations that showed durable tumor regression across multiple sarcoma subtypes. Storm positioned METTL3 inhibition as a way to address vulnerabilities in sarcomas that often lack response to standard targeted therapy or immunotherapy. Investors will now watch for Phase 2 results across indications, with Storm stating the program could support pathways that accelerate approvals if efficacy signals hold. The first patient in the Phase 2 trial was already dosed, putting the program on an execution-driven timeline.